The development of a new drug takes over 10 years and costs approximately US $2.6 billion. Virtual compound screening (VS) is a part of efforts to reduce this cost. Learning-to-rank is a machine learning technique in information retrieval that was recently introduced to VS. It works well because the application of VS requires the ranking of compounds. Moreover, learning-to-rank can treat multiple heterogeneous experimental data because it is trained using only the order of activity of compounds. In this study, we propose PKRank, a novel learning-to-rank method for ligand-based VS that uses a pairwise kernel and RankSVM. PKRank is a general case of the method proposed by Zhang et al. with the advantage of extensibility in terms of kernel selection. In comparisons of predictive accuracy, PKRank yielded a more accurate model than the previous method.